Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a phenotype of chronic rhinosinusitis characterized by the presence of nasal polyps. To date, medical therapy and surgery can manage the disease in most cases. 1 Fokkens W.J. Lund V.J. Hopkins C. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58: 1-464 Google Scholar However, despite improvements in surgical techniques, CRSwNP is characterized by relapses in severe cases, thus leading to the study of biologic drugs such as mepolizumab, antagonizing interleukin (IL)-5. Experimental and clinical evidence demonstrates that CRSwNP is driven by a type 2 immune response and displays eosinophil infiltration, mucosal inflammation, and hyperplasia of the epithelium. 2 Bachert C. Marple B. Hosemann W. Cavaliere C. Wen W. Zhang N. Endotypes of chronic rhinosinusitis with nasal polyps: pathology and possible therapeutic implications. J Allergy Clin Immunol Pract. 2020; 8: 1514-1519 Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar Furthermore, it has been described that vascular endothelial growth factor (VEGF) is strongly up-regulated in the mucosa of patients with CRSwNP, promoting edema and epithelial cell growth in nasal polyps when compared with normal mucosa. 3 Wittekindt C. Hess A. Bloch W. Sultanie S. Michel O. Immunohistochemical expression of VEGF and VEGF receptors in nasal polyps as compared to normal turbinate mucosa. Eur Arch Otorhinolaryngol. 2002; 259: 294-298 Crossref PubMed Scopus (56) Google Scholar Notably, other reports found that IL-5 stimulates VEGF production, which may influence immune cells’ activity in inflammatory conditions. 4 Puxeddu I. Ribatti D. Crivellato E. Levi-Schaffer F. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. J Allergy Clin Immunol. 2005; 116: 531-536 Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar